ERBB2 and triple-negative breast carcinoma: Hormone therapy and anti-HER2 drugs are not choices for women with triple-negative breast cancer, there is limited scope of chemotherapy; the overall survival rate of TNBC currently is around 77% (American Cancer Society) [4].